Fluoxetine

Product manufactured by Direct Rx

Application Nr Approved Date Route Status External Links
ANDA090223 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Fluoxetine Is Indicated For The Treatment Of: · Acute And Maintenance Treatment Of Major Depressive Disorder [See Clinical Studies (14.1)]. · Acute And Maintenance Treatment Of Obsessions And Compulsions In Patients With Obsessive Compulsive Disorder (Ocd) [See Clinical Studies (14.2)]. · Acute And Maintenance Treatment Of Binge-Eating And Vomiting Behaviors In Patients With Moderate To Severe Bulimia Nervosa [See Clinical Studies (14.3)]. · Acute Treatment Of Panic Disorder, With Or Without Agoraphobia [See Clinical Studies (14.4)]. Fluoxetine And Olanzapine In Combination Is Indicated For The Treatment Of: · Acute Treatment Of Depressive Episodes Associated With Bipolar I Disorder. Fluoxetine Monotherapy Is Not Indicated For The Treatment Of Depressive Episodes Associated With Bipolar I Disorder. When Using Fluoxetine And Olanzapine In Combination, Also Refer To The Clinical Studies Section Of The Package Insert For Symbyax ®.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Fluoxetine Hydrochloride FLUOXETINE HYDROCHLORIDE ZINC1530637

Comments